Protective immunity remains intact after antibody removal by means of proteasome inhibition

Transplantation

Volumn 90, Issue 12, 2010, Pages 1493-1498

  Everly, Matthew J ^a   Terasaki, Paul I ^b   Hopfield, Judy ^a   Trivedi, Hargovind L ^c   Kaneku, Hugo ^b  

^a One Lambda Inc   (United States)

^b Terasaki Foundation   (United States)

^c Institute of Transplantation Sciences   (India)

Author keywords

Alloantibodies; Measles; Proteasome; Tetanus toxoid; Transplantation

Indexed keywords

BORTEZOMIB; HLA ANTIBODY; HLA ANTIGEN; IMMUNOGLOBULIN G; MEASLES ANTIBODY; PROTEASOME; PROTEASOME INHIBITOR; RITUXIMAB; TETANUS TOXOID; VACCINE;

ADULT; ANTIBODY PRODUCTION; ARTICLE; CLINICAL ARTICLE; DRUG SAFETY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HLA SYSTEM; HUMAN; HUMORAL IMMUNITY; KIDNEY GRAFT; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MALE; MEASLES; PLASMAPHERESIS; PRIORITY JOURNAL;

APOPTOSIS; BORONIC ACIDS; COMBINED MODALITY THERAPY; CREATININE; ENZYME-LINKED IMMUNOSORBENT ASSAY; FOLLOW-UP STUDIES; GRAFT SURVIVAL; HLA ANTIGENS; HUMANS; IMMUNITY; IMMUNOGLOBULIN G; KIDNEY TRANSPLANTATION; LIVING DONORS; PLASMAPHERESIS; PROTEASE INHIBITORS; PROTEASOME ENDOPEPTIDASE COMPLEX; PYRAZINES; TRANSPLANTATION, HOMOLOGOUS; TREATMENT FAILURE;

EID: 78650810252     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e3181ff87b1     Document Type: Article

References (18)

1. Blink EJ, Light A, Kallies A, et al. Early appearance of germinal centerderived memory B cells and plasma cells in blood after primary immunization. J Exp Med 2005; 201: 545.
2. Odendahl M, Mei H, Hoyer BF, et al. Generation of migratory antigenspecific plasma blasts and mobilization of resident plasma cells in a secondary immune response. Blood 2005; 105: 1614.
3. Zarkhin V, Kambham N, Li L, et al. Characterization of intra-graft B cells during renal allograft rejection. Kidney Int 2008; 74: 664.
4. Radbruch A, Muehlinghaus G, Luger EO, et al. Competence and competition: The challenge of becoming a long-lived plasma cell. Nat Rev Immunol 2006; 6: 741.
5. Meister S, Schubert U, Neubert K, et al. Extensive immunoglobulin production sensitizes myeloma cells for proteasome inhibition. Cancer Res 2007; 67: 1783.
6. Gass JN, Gunn KE, Sriburi R, et al. Stressed-out B cells? Plasma-cell differentiation and the unfolded protein response. Trends Immunol 2004; 25: 17.
7. Kim R, Emi M, Tanabe K, et al. Role of the unfolded protein response in cell death. Apoptosis 2006; 11: 5.
8. Nawrocki ST, Carew JS, Pino MS, et al. Bortezomib sensitizes pancreatic cancer cells to endoplasmic reticulum stress-mediated apoptosis. Cancer Res 2005; 65: 11658.
9. Obeng EA, Carlson LM, Gutman DM, et al. Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells. Blood 2006; 107: 4907.
10. Everly MJ, Everly JJ, Susskind B, et al. Proteasome inhibition reduces donor-specific antibody levels. Transplant Proc 2009; 41: 105.
11. Everly MJ, Everly JJ, Susskind B, et al. Bortezomib provides effective therapy for antibody- and cell-mediated acute rejection. Transplantation 2008; 86: 1754.
12. Idica A, Kaneku H, Everly MJ, et al. Elimination of post-transplant donor-specific HLA antibodies with bortezomib. Clin Transpl 2008: 229.
13. Neumann J, Tarrasconi H, Bortolotto A, et al. Acute humoral rejection in a lung recipient: Reversion with bortezomib. Transplantation 2010; 89: 125.
14. Perry DK, Burns JM, Pollinger HS, et al. Proteasome inhibition causes apoptosis of normal human plasma cells preventing alloantibody production. Am J Transplant 2009; 9: 201.
15. Trivedi HL, Terasaki PI, Feroz A, et al. Abrogation of anti-HLA antibodies via proteasome inhibition. Transplantation 2009; 87: 1555.
16. Everly JJ, Walsh RC, Alloway RR, et al. Proteasome inhibition for antibody- mediated rejection. Curr Opin Organ Transplant 2009; 14: 662.
17. Walsh RC, Everly JJ, Brailey P, et al. Proteasome inhibitor-based primary therapy for antibody-mediated renal allograft rejection. Transplantation; 2010; 89: 277.
18. Amanna IJ, Carlson NE, Slifka MK. Duration of humoral immunity to common viral and vaccine antigens. N Engl J Med 2007; 357: 1903.